Whalesbook
### The Growth Narrative
Fortis Healthcare has demonstrated considerable financial momentum through the first nine months of fiscal year 2026. Consolidated revenue reached ₹6,763 crore with an EBITDA margin of 22.9%, marking a 17.1% year-over-year increase. This surge was largely propelled by the hospital segment, which expanded its revenue by 19.1%, maintaining a healthy occupancy rate of 69% and an Average Revenue Per Operating Bed (ARPOB) of ₹70,500.
The diagnostics division, rebranded as Agilus Diagnostics, also contributed positively. It recorded revenue growth of 7.7% to ₹1,139 crore, with operating EBITDA more than doubling to ₹275 crore, expanding margins to 24.1% from 17.5%. The business processed 30.7 million tests, supported by network expansion and over 550 new customer touch-points.
Fortis continues its cluster-based expansion strategy, adding approximately 750 operational beds year-to-date through acquisitions and leases. The recent ₹430-crore acquisition of People Tree Hospitals in Bengaluru adds 125 beds to its network. Furthermore, the company is enhancing its service portfolio with specialized units like Adayu for mental health and has announced plans to add over 3,200 beds within the next three years.
### Valuation Scrutiny
Despite the robust operational performance, Fortis Healthcare is trading at a notable valuation premium. Enterprise Value to EBITDA multiples are projected at 27x for FY27E and 23x for FY28E. Current trailing twelve-month (TTM) P/E ratios cited in recent analyses range from approximately 73.61x to 86.40x. Historical P/E data shows a significant increase, with some reports indicating a peak P/E around 74.3x in March 2025. Compared to peers, Fortis's P/E ratio often appears at the higher end, with Apollo Hospitals trading at around 60.6x to 70.3x and Max Healthcare Institute at approximately 71.63x to 98.76x. Some analyses suggest Fortis's P/E ratio is higher than the sector average, raising concerns about potential overvaluation relative to its industry peers. While the stock has seen significant appreciation, with a 53.85% change over the past year, its current multiples require careful consideration against its growth trajectory.
### The Forensic Bear Case
Investor caution is warranted due to past regulatory actions and ongoing legal challenges. In May 2022, the Securities and Exchange Board of India (SEBI) imposed penalties totaling ₹38.75 crore on 32 entities, including Fortis Healthcare Holdings, in connection with alleged diversion of ₹397 crore from Fortis Healthcare Ltd (FHL) to RHC Holding via a subsidiary. These events stemmed from a 2018 media report highlighting promoter fund extraction and auditor concerns.
Furthermore, Fortis is involved in a significant lawsuit initiated by a US-based organization, Emqore Envesecure, for alleged copyright infringement and tortious interference, seeking damages estimated at $6.5 billion. While Fortis Healthcare has stated it has strong grounds to dismiss these allegations and anticipates no operational or financial impact, the lawsuit remains an outstanding risk factor. These historical governance issues and legal entanglements cast a shadow over the current growth narrative.
### Sector Tailwinds and Competitive Positioning
The Indian healthcare sector continues to be a strong growth engine, fueled by rising incomes, an expanding middle class, demographic shifts including an aging population, and the increasing prevalence of lifestyle-related diseases. The demand for diagnostic services, in particular, is projected to grow substantially, with the market expected to reach approximately $34.7 billion by 2030. Technological advancements, including AI and digital health, are further accelerating sector evolution and improving healthcare delivery efficiency.
Within this expanding market, Fortis competes with established players like Apollo Hospitals and Max Healthcare Institute. While Fortis is executing strategic expansion, some peer comparisons indicate potential areas for improvement in capital utilization, with Fortis's Return on Capital Employed (ROCE) and Return on Equity (ROE) noted as relatively lower than some key competitors in certain analyses. However, Fortis's hospital revenue growth of 19.1% and diagnostics segment's margin expansion demonstrate its competitive ability to capture market share.
### Future Outlook
Analysts have maintained a 'Buy' recommendation for Fortis Healthcare with a target price of ₹1,038, suggesting a potential upside from the current market price. The company's strategic expansion plans and strong performance in key segments provide a foundation for continued growth. However, investors must balance these positive outlooks against the company's premium valuation multiples and the persistent overhang of past regulatory penalties and ongoing litigation. The ability to sustain earnings growth at a pace that justifies its current market valuation will be critical for future performance.